Rapport Therapeutics, Inc.RAPP

Rapport Therapeutics, Inc. is focused on neurology. The company's investigational drug, RAP-219, has shown various median percent reductions in Clinical Seizures, including 90%, 85%, 78%, 77%, 75%, 68%, and 59%. For Long Episodes (LEs), RAP-219 demonstrated median percent reductions of 80%, 75%, 71%, 69%, and 68%. Seizure freedom rates for RAP-219 were reported at 24%, 20%, and 12%. RAP-219 has a half-life of 22 days. In terms of safety, 2 patients experienced treatment-related adverse events and 3 patients experienced serious adverse events with RAP-219. The company plans to initiate Phase 3 trials for RAP-219 in the second quarter of 2026 and the first half of 2027. Initial data from an open-label long-term safety trial (OLE) for RAP-219 is expected in the second half of 2026, with Phase 2 trial topline results anticipated in the first half of 2027. Initial PK results for RAP-219 from a Phase 1 trial are expected in 2027. A total of 30 adult patients were enrolled in a study for RAP-219.